1
|
Azuma I, Mizuno T, Morita K, Suzuki Y, Kusuhara H. Investigation of the usefulness of liver-specific deconvolution method by establishing a liver benchmark dataset. NAR Genom Bioinform 2024; 6:lqad111. [PMID: 38187088 PMCID: PMC10768887 DOI: 10.1093/nargab/lqad111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 10/31/2023] [Accepted: 12/16/2023] [Indexed: 01/09/2024] Open
Abstract
Immune responses in the liver are related to the development and progression of liver failure, and precise prediction of their behavior is important. Deconvolution is a methodology for estimating the immune cell proportions from the transcriptome, and it is mainly applied to blood-derived samples and tumor tissues. However, the influence of tissue-specific modeling on the estimation results has rarely been investigated. Here, we constructed a system to evaluate the performance of the deconvolution method on liver transcriptome data. We prepared seven mouse liver injury models using small-molecule compounds and established a benchmark dataset with corresponding liver bulk RNA-Seq and immune cell proportions. RNA-Seq expression for nine leukocyte subsets and four liver-associated cell types were obtained from the Gene Expression Omnibus to provide a reference. We found that the combination of reference cell sets affects the estimation results of reference-based deconvolution methods and established a liver-specific deconvolution by optimizing the reference cell set for each cell to be estimated. We applied this model to independent datasets and showed that liver-specific modeling is highly extrapolatable. We expect that this approach will enable sophisticated estimation from rich tissue data accumulated in public databases and to obtain information on aggregated immune cell trafficking.
Collapse
Affiliation(s)
- Iori Azuma
- Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - Tadahaya Mizuno
- To whom correspondence should be addressed. Tel: +81 3 5841 4771; Fax: +81 3 5841 4766;
| | - Katsuhisa Morita
- Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - Yutaka Suzuki
- Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan
| | - Hiroyuki Kusuhara
- Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| |
Collapse
|
2
|
Sampaziotis F, Muraro D, Tysoe OC, Sawiak S, Beach TE, Godfrey EM, Upponi SS, Brevini T, Wesley BT, Garcia-Bernardo J, Mahbubani K, Canu G, Gieseck R, Berntsen NL, Mulcahy VL, Crick K, Fear C, Robinson S, Swift L, Gambardella L, Bargehr J, Ortmann D, Brown SE, Osnato A, Murphy MP, Corbett G, Gelson WTH, Mells GF, Humphreys P, Davies SE, Amin I, Gibbs P, Sinha S, Teichmann SA, Butler AJ, See TC, Melum E, Watson CJE, Saeb-Parsy K, Vallier L. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science 2021; 371:839-846. [PMID: 33602855 PMCID: PMC7610478 DOI: 10.1126/science.aaz6964] [Citation(s) in RCA: 144] [Impact Index Per Article: 48.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 05/01/2020] [Accepted: 12/09/2020] [Indexed: 02/02/2023]
Abstract
Organoid technology holds great promise for regenerative medicine but has not yet been applied to humans. We address this challenge using cholangiocyte organoids in the context of cholangiopathies, which represent a key reason for liver transplantation. Using single-cell RNA sequencing, we show that primary human cholangiocytes display transcriptional diversity that is lost in organoid culture. However, cholangiocyte organoids remain plastic and resume their in vivo signatures when transplanted back in the biliary tree. We then utilize a model of cell engraftment in human livers undergoing ex vivo normothermic perfusion to demonstrate that this property allows extrahepatic organoids to repair human intrahepatic ducts after transplantation. Our results provide proof of principle that cholangiocyte organoids can be used to repair human biliary epithelium.
Collapse
Affiliation(s)
- Fotios Sampaziotis
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Medicine, University of Cambridge,Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust,Correspondence to: Fotios Sampaziotis, ; Ludovic Vallier,
| | | | - Olivia C. Tysoe
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK
| | - Stephen Sawiak
- University of Cambridge, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Timothy E. Beach
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK
| | - Edmund M. Godfrey
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust
| | - Sara S. Upponi
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust
| | | | | | - Jose Garcia-Bernardo
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK
| | - Krishnaa Mahbubani
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK
| | | | - Richard Gieseck
- Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA
| | - Natalie L. Berntsen
- Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway,Research Institute of Internal Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Victoria L. Mulcahy
- Department of Medicine, University of Cambridge,Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK
| | - Keziah Crick
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Corrina Fear
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Sharayne Robinson
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Lisa Swift
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Laure Gambardella
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Medicine, University of Cambridge
| | - Johannes Bargehr
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Medicine, University of Cambridge,Division of Cardiovascular Medicine, University of Cambridge, ACCI Level 6, Box 110, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK
| | | | | | - Anna Osnato
- Wellcome and MRC Cambridge Stem Cell Institute
| | - Michael P. Murphy
- MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | | | - William T. H. Gelson
- Department of Medicine, University of Cambridge,Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust
| | - George F. Mells
- Department of Medicine, University of Cambridge,Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust,Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK
| | | | - Susan E. Davies
- Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Irum Amin
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Paul Gibbs
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Sanjay Sinha
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Medicine, University of Cambridge
| | - Sarah A. Teichmann
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK,Cavendish Laboratory, JJ Thomson Ave, Cambridge CB3 0HE, UK
| | - Andrew J Butler
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Teik Choon See
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust
| | - Espen Melum
- Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway,Research Institute of Internal Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway,Section for Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway,Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Christopher J. E. Watson
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, and the NIHR Blood and Transplant Research Unit (BTRU) at the,University of Cambridge in collaboration with Newcastle University and in partnership with NHS Blood and Transplant (NHSBT), Cambridge, UK
| | - Kourosh Saeb-Parsy
- Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Ludovic Vallier
- Wellcome and MRC Cambridge Stem Cell Institute,Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research centre, Cambridge, UK,Correspondence to: Fotios Sampaziotis, ; Ludovic Vallier,
| |
Collapse
|
3
|
Vilas-Boas V, Gijbels E, Cooreman A, Van Campenhout R, Gustafson E, Leroy K, Vinken M. Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis. Chem Res Toxicol 2019; 32:1327-1334. [PMID: 31243985 DOI: 10.1021/acs.chemrestox.9b00148] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A frequent side effect of many drugs includes the occurrence of cholestatic liver toxicity. Over the past couple of decades, drug-induced cholestasis has gained considerable attention, resulting in a plethora of data regarding its prevalence and mechanistic basis. Likewise, several food additives and dietary supplements have been reported to cause cholestatic liver insults in the past few years. The induction of cholestatic hepatotoxicity by other types of chemicals, in particular synthetic compounds, such as industrial chemicals, biocides, and cosmetic ingredients, has been much less documented. Such information can be found in occasional clinical case reports of accidental intake or suicide attempts as well as in basic and translational study reports on mechanisms or testing of new therapeutics in cholestatic animal models. This paper focuses on such nonpharmaceutical and nondietary synthetic chemical inducers of cholestatic liver injury, in particular alpha-naphthylisocyanate, 3,5-diethoxycarbonyl-1,4-dihydrocollidine, methylenedianiline, paraquat, tartrazine, triclosan, 2-octynoic acid, and 2-nonynoic acid. Most of these cholestatic compounds act by similar mechanisms. This could open perspectives for the prediction of cholestatic potential of chemicals.
Collapse
Affiliation(s)
- Vânia Vilas-Boas
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Eva Gijbels
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Axelle Cooreman
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Raf Van Campenhout
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Emma Gustafson
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Kaat Leroy
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| | - Mathieu Vinken
- Department of In Vitro Toxicology and Dermato-Cosmetology , Vrije Universiteit Brussel , Brussels , Belgium
| |
Collapse
|